FDA and the Future of Generative AI Medical Devices
MedTech Leading Voice - Issue 190
📝 From the Editor
FDA’s generative AI docket shows where clinical AI oversight is heading, and who carries the burden of proof is the open question. This week also brings new EU harmonised standards under MDR and IVDR, amendments to Canada’s Medical Devices Regulations and FDA’s updated cybersecurity FAQ.
— Sean Smith
🧠 Featured Post
540 FDA Comments Reveal the Fault Lines in Regulating Clinical AI
Dr. Axel Sylvan, Chief Medical Officer at Hopper Healthcare, used AI assistance to review all 540 comments and 444 attachments, about 4,250 pages, on FDA’s discussion paper on generative AI-enabled medical devices. FDA proposes rating risk on two axes: how independently a device acts, and how bad it is to rely on a wrong answer. Nearly two-thirds of commenters support the framework, and those wanting tougher rules outnumber those wanting lighter ones by more than three to one. Postmarket monitoring came up in 387 of the 536 relevant submissions. The shared demand was that every safeguard be shown to work.
For MedTech teams, the sharpest split is over who carries the risk. Commenters disagree on whether a device can launch with less evidence if the manufacturer commits to closer monitoring afterward.
They also disagree on whether independent evaluation should be mandatory, and how responsibility is shared among device makers, model developers and health systems. Device makers building on foundation models face practical gaps: model retirement notices can be as short as 45 to 60 days, and FDA’s device records don’t show which model a device is built on. Axel closes with five priorities for FDA’s next step.
📌 This Week’s Top Posts (In no special order)
- New EU harmonised standards supporting MDR and IVDR compliance were announced by Mario Gabrielli Cossellu.
- Concerns over Switzerland’s proposed medical device market access reforms were raised by Peter Studer.
- Four EU MDR medical device risk classes and their regulatory requirements were explained by Easy Medical Device.
- The distinction between a Declaration of Conformity and supporting technical documentation was clarified by Beat Keller.
- Key disagreements across 540 FDA comments on clinical AI regulation were examined by Dr. Axel Sylvan.
- Five key global MedTech regulatory trends from September and October, spotlighted by David Filmore.
- A free white paper on defining and documenting medical device intended purpose was shared by EU MDR Compliance.
- Four key amendments to Canada’s Medical Devices Regulations broken down by Darrin Carlson.
- FDA’s updated cybersecurity FAQ and its implications for medical device submissions were summarized by Nicholas Butt.
- Recommendations for a practical, evidence-based revision of IEC 60601-1 Edition 4 were discussed by Georg Heidenreich.
- Team NB’s concerns regarding Expert Panel assessments under Article 54 MDR detailed by Hatem Rabeh.
🎯 Featured Event
The Business Case for Quality, Part 2: Steps 6 to 10 of MDIC’s Ten-Step Program Under QMSR
Friday, November 20, 2026 | 11:00 AM ET (8:00 AM PT, 5:00 PM CET)
Can anyone in your company raise a quality concern without paying for it?
Under the QMSR, FDA treats culture of quality as an inspection objective, and management review is now open to investigators. A company can have compliant procedures while the behaviors behind them produce repeat CAPAs, late escalations and recurring complaints.
Those behaviors depend on three things. Does each person know what quality means in their own job? Can they raise a concern safely? What does the company measure and reward? MDIC’s ten-step program gives leaders a way to build each of these deliberately.
On September 11, Michelle Lott, RAC, and Tianna Benson of leanRAQA covered the first five steps with more than 150 attendees, and the hour ran out at step five. On November 20, they return to Friday In Focus to finish the program:
- Step 6: Defining quality at the individual level, so sales and marketing, engineering, operations and executive management each know what they own
- Step 7: The speak-up test. Six questions that show whether people can raise a concern, open a CAPA or change their own procedures without going through Quality
- Step 8: Benchmarking against FDA’s own data, including the most frequent inspection citations of FY2026 so far and the results of FDA’s Case for Quality pilots
- Step 9: Quality metrics that measure behavior, and a five-stage loop for acting on complaint, service and MDR signals
- Step 10: Recognizing and rewarding quality behaviors at the peer, manager and leadership levels
Michelle Lott, RAC, is Principal and Founder of leanRAQA. She has worked in regulatory affairs and quality assurance for about 20 years and serves on FDA’s GMP Advisory Committee. Tianna Benson is a biomedical engineer and Senior RA/QA Manager at leanRAQA.
For quality and regulatory leaders, operations and engineering managers, executives responsible for management review under the QMSR, and the consultants who support them.
Missed Part 1?Watch the replay (Passcode: y73U4$X%). Part 2 opens with a short recap.
Recording and slides go to everyone who registers. Bring your questions and the quality culture problems you’re working on.
🗓️ Upcoming Webinars
- Thursday, November 19 | 11:00 AM ET — Patient Personas: Information or Abomination?, featuring Merrill Zavod (UX & Human Factors, ClariMed). Register Now >>
- Friday, November 20 | 11:00 AM ET — The Business Case for Quality, Part 2, featuring Michelle Lott, RAC (Principal and Founder) and Tianna Benson (Senior Regulatory and Quality Manager). Register Now >>
- Friday, November 27 | 11:00 AM ET — How Has AI Affected Your Business? Eighteen Months of Change in MedTech, featuring Joe Hage (Founder, Medical Devices Group) and Nic Anderson (Founder, Nic Anderson Consulting). Register Now >>
- Friday, December 4 | 11:00 AM ET — Periodic Safety Update Reports Under the EU MDR, featuring Saman Tavana, PhD, CEng (Senior Product Assessor, SGS). Register Now >>
💥 Weekly 510(k) Roundup
November 9, 2026 | From Marcus Engineering, LLC
51 clearances this week, including 23 first-time clearances (🚀).
Featured clearances:
- 🚀 The Jacobs Institute: 3D Anatomical Model. Turns medical scans into physical models doctors can hold, examine and use to practice procedures before surgery. Engineers can also use them to test new devices.
- MolecuLight: OxySight. A new imaging feature for its handheld wound camera that uses light to assess oxygen levels in wounded tissue. It adds oxygenation imaging to a system that already detects bacteria.
- 🚀 BeamWorks Inc.: CadAI-B Dx. AI for breast ultrasound that identifies and measures suspicious areas and assigns a cancer-risk score from 0 to 100, giving doctors another assessment when deciding whether more testing is needed.
📋 Regulatory Roundup
Monday, 9 November 2026 | By Martin King
Regulatory intelligence has to turn into regulatory action. This week’s flipbook edition covers eight themes:
🔴 Guidance to implementation: NMPA, Health Canada, European Commission 🔴 Submission quality and structured data: CDISC, Health Canada, MHRA, European Commission 🔴 Cybersecurity and data protection: ENISA, NIST, MedTech Europe 🔴 Lifecycle quality management: PIC/S, Swissmedic, FDA, Medical Device Authority (Malaysia) 🔴 Clinical evidence and innovation: European Commission, EMA, NMPA, CDISC 🔴 Market access and cooperation: HPRA, MedTech Europe, Health Canada, Medical Device Authority 🔴 Harmonisation and local requirements: Health Canada, European Commission, Swissmedic, NMPA 🔴 Whole-lifecycle oversight: global regulatory authorities
🎤 In Case You Missed It
Architecting a Claims Support System
Friday In Focus, November 13 - Ethan Drower, Co-Founder and CEO of CiteMed, showed 181 attendees from 33 countries how to link every product claim to the evidence behind it.
📊 What the polls showed: Only 14 of 96 use a claims register or MLR system ↳ 66 rely on a spreadsheet, or trace claims through the CER, IFU and files when asked ↳ 62 of 90 already have an approved AI assistant
🧩 Why claims get stuck: regulatory wants the safest claim, marketing wants the strongest one, and leadership wants both with no added staff.
🛠️ The fix, in three parts: detect claims wherever they appear, grade them against the evidence, and store the results where any team can search them. “Nobody likes going through the CER,” Ethan said.
⚖️ What’s at stake: a testimonial carrying an implied claim cost Outset 50% of its share price. Dexcom’s evidence won a finger-stick replacement indication, and Medicare coverage followed.
Panelist Madison Hedrick, MA , Senior Medical Writer at Artivion, made the case for giving clinical teams more of the work: “clinical’s looking at the data.”
Watch the replay >> | Get the slides >>
🔥 Postscript
Feeling invisible?
When a buyer searches your specialty without your name, do they find you?
The free MLVAI Visibility Audit is a one-page report on how you appear across Google, LinkedIn, and AI search. It’s built for MedTech experts in regulatory, quality, clinical, human factors, cybersecurity, and similar fields.
↳ An AI visibility score out of 100 ↳ Seven rated checks across three areas: Documented, Findable and Verifiable ↳ The evidence already working for you ↳ Three priority fixes, with the effort each takes
A person reviews every report, and it arrives by email within 24 to 48 hours.
Sean 🐝